Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes anticancer immunity by inducing the contraction of peripheral blood immunosuppressive myeloid and regulatory T-cell compartments, paralleled by enhanced intratumor Th1/cytotoxic responses and an enrichment of IFNγ and other immune signatures associated with better clinical outcomes in patients with cancer. Our findings lay the foundations for phase II/III clinical trials aimed at investigating FMD antitumor efficacy in combination with standard antineoplastic treatments. Significance: Cyclic FMD is well tolerated and causes remarkable systemic metabolic changes in patients with different tumor types and treated with concomitant antitumor therapies. In addition, the FMD reshapes systemic and intratumor immunity, finally activating several antitumor immune programs. Phase II/III clinical trials are needed to investigate FMD antitumor activity/efficacy. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3. The fasting-mimicking diet (FMD) reshapes intratumor immunity in patients with breast cancer. A, Time points of blood and tissue sample collection in the DigesT trial (NCT03454282). T1, initiation of the FMD; T2, end of the FMD; T3, surgery; T4, approximately 30 days after surgery. B, Left, IHC evaluation of intratumor IGFR1 and phosphorylated IGFR1 (pIGF1R; brown dots) in pre- and post-FMD tumor samples from one indicative patient (magnification of 200×). B, Right, Box plots showing results of IHC analyses (reported as H-score) of IGF1R and pIGF1R in matched pre- and post-FMD tumor samples in 18 patients enrolled in the DigesT trial (NCT03454282). All P values for the indicated comparisons were determined by paired Wilcoxon test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Box plots indicate median values, with the boundaries of the rectangle representing the first and third quartiles, while vertical black lines extend to the extreme data points that are no more than 1.5 times the interquartile range. Each red dot represents one patient; couples of plots connected by the same black line refer to the same patient before and after the FMD. C, Representative images of hematoxylin and eosin staining (H&E) and IHC evaluations of intratumor CD8+ T cells and CD68+ macrophages in pre-FMD (T1) and post-FMD (T3) tumor samples from two representative patients (magnification of ×200). D, Top plots, box plots showing the IHC quantification of percentage (area) and absolute average numbers (per high-power field; HPF) of intratumor stromal CD8+ cells, absolute average number (per HPF) of intraepithelial CD8+ cells, absolute average number (per HPF) of CD68+ macrophages, and the ratio between stromal CD8+ cells (absolute average number per HPF) and CD68+ macrophages (absolute average number per HPF) in pre-FMD versus post-FMD tumor specimens. Box plot showing the CD8A/CD68 transcript ratio in post-FMD as compared with pre-FMD tumor specimens. Box plots indicate median values of the frequencies of each immune cell population/gene transcript, with the boundaries of the rectangle representing the first and third quartiles, while vertical black lines extend to the extreme data points that are no more than 1.5 times the interquartile range. Each red dot represents one patient; couples of dots connected by the same black line refer to data from the same patient pre- and post-FMD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by paired Wilcoxon test for the indicated comparisons. D, Bottom plots, correlation between CD8+ T cells by IHC and CD8A gene expression, and between CD68+ macrophages by IHC and CD68 gene expression; box plot showing the CD8A/CD68 transcript ratio in post-FMD as compared with pre-FMD tumor specimens. E, Heat map displaying scores of enrichment of leukocyte subsets (XCell, Charoentong list) that are differentially modulated after the FMD [T3 vs. T1, paired Wilcoxon test, P < 0.05, Benjamini–Hochberg (B-H) false discovery rate (FDR) < 0.1]. aDC, activated DCs; CD4+ and CD8+ Tcm: CD4+ and CD8+ central memory T lymphocytes; NKT, natural killer T cells; pDC, plasmacytoid dendritic cells; Tem, effector memory T lymphocytes. F, Box plots representing scores of individual leukocyte subsets modulated in post-FMD versus pre-FMD tumor specimens. G, Matrix correlation displaying Spearman correlation coefficients between RNA-seq data (CD8A and CD68 transcripts, CD8+ T-cell, and Macrophage enrichment scores), and IHC assessment of CD8+ T cells and CD68+ cells.](https://figures.cochat.ai/paper-figures/b95f98bf014f4faeb2aa34f1018c5ae9/fasting-mimicking-diet-is-safe-and-reshapes-metabolism-and-antitumor-immunity-in-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In humans, a fasting-mimicking diet decreases immunosuppressive myeloid cells while increasing CD8+ T cells and NK cells.141”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [141]
In the citing paper
“Pharmacological treatments aimed at mimicking states of nutrient scarcity, as well as different dietary regimens based on continuous CR, intermittent fasting, ketogenesis (through the elimination of carbohydrates), or depletion of specific nutrients (such as methionine) are being actively explored in this regard with encouraging results.[238][239][240][241][242][243][244]”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [240]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 1×
“Finally, when macrophages were stratified into M1-like and M2-like subtypes (15), we detected an increase of M1-like macrophages after the FMD, while M2-like macrophages did not significantly change (Supplementary Fig.”
BackgroundRecommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · cited 1×
“S5H), which suggests the acquisition of an effector-memory phenotype (12).”
BackgroundLDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“3C and D), the CD8/CD68 (protein) and CD8A/CD68 (gene transcript) ratios, which were previously associated with better prognosis in patients with cancer (13), were increased in post-FMD tumor specimens (Fig.”
BackgroundCancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517 · cited 2×
“Because IL6 plays an important role in the pathogenesis of cachexia (28), FMD-induced upregulation of the IL6/ SOCS3/LIF signature at the tumor level may raise concerns about a potential cachexia-inducing effect of the FMD.”
BackgroundPhosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Cited by
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“FMDs such as cyclic fasting, low-carbohydrate diets and calorie restriction could reshape anticancer immunity in cancer patients by enriching IFN-γ, enhancing intratumoral Th1/cytotoxic responses, and inducing the contraction of regulatory T-cell compartments, and stimulating other immune signatures related to favorab…”
BackgroundZhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Metadata
- Authors
- Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., Lalli, L., Chiodoni, C., Cancila, V., Zanardi, F., Ajazi, A., Cortellino, S., Vallacchi, V., Squarcina, P., Cova, A., Pesce, S., Frati, P., Mall, R., Corsetto, P. A., Rizzo, A. M., Ferraris, C., Folli, S., Garassino, M. C., Capri, G., Bianchi, G., Colombo, M. P., Minucci, S., Foiani, M., Longo, V. D., Apolone, G., Torri, V., Pruneri, G., Bedognetti, D., Rivoltini, L., & de Braud, F.
- Affiliations
- IFOM (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Milan (IT)
- Sidra Medical and Research Center (QA)
- European Institute of Oncology (IT)
- University of Palermo (IT)
- Hamad bin Khalifa University (QA)
- University of Southern California (US)
- Mario Negri Institute for Pharmacological Research (IT)
- 1Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Corresponding author
- Vernieri, Claudio
- Rivoltini, Licia
- ORCID
- Vernieri, Claudio
- Fucà, Giovanni
- Ligorio, Francesca
- Huber, Veronica
- Vingiani, Andrea
- Rinchai, Darawan
- Frigè, Gianmaria
- Belfiore, Antonino
- Lalli, Luca
- Chiodoni, Claudia
- Cancila, Valeria
- Zanardi, Federica
- Ajazi, Arta
- Cortellino, Salvatore
- Vallacchi, Viviana
- Mall, Raghvendra
- Ferraris, Cristina
- Garassino, Marina Chiara
- Colombo, Mario Paolo
- Minucci, Saverio
- Foiani, Marco
- Longo, Valter Daniel
- Apolone, Giovanni
- Venue
- Cancer Discovery
- Published
- 2021-11-17
- Volume
- 12
- Issue
- 1
- Pages
- 90-107
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9762338
- OpenAlex
- W3212242980
- Cited by
- 319
- References
- 50
- Citations by year
- 2026: 43 · 2025: 73 · 2024: 82 · 2023: 78 · 2022: 42 · 2021: 1
- FWCI
- 31.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (MFAG-2019 n. 22977, IG-2017 n.20752)
- Agenzia Italiana del Farmaco, Ministero della Salute (TRANSCAN-2, code n. TRS-2016-00000393)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- fasting-mimicking diet, antitumor immunity, cancer metabolism, regulatory T cells, myeloid cells, Th1/Treg balance, interferon-gamma, immune checkpoint blockade, blood glucose, safety and tolerability, transcriptomics, deep phenotyping
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Fasting, Female, Humans, Male, Middle Aged, Prospective Studies, Colorectal Neoplasms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0030
- The paper
- Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., Lalli, L., Chiodoni, C., Cancila, V., Zanardi, F., Ajazi, A., Cortellino, S., Vallacchi, V., Squarcina, P., Cova, A., . . . de Braud, F. (2022). Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.